ATENOLOL IN EPISODIC MIGRAINE PROPHYLAXIS: A REVIEW
DOI:
https://doi.org/10.22159/ajpcr.2022.v15i6.44496Keywords:
Atenolol, Migraine, Hypertension, Coronary artery, Asthmatic, DiabeticAbstract
Atenolol seems to reduce blood vessel dilation, which is known to contribute to migraine. It reduces electrical activity of nervous system and reduces it excitability. Atenolol is a β1-cardioselective beta-blocker that influences the heart circulation through veins and arteries. Primarily, it is used to treat high blood pressure and heart-related chest pain. It is also used as a supplement subsequent to a heart attack to lower the risk of death. Atenolol has shown efficacy in prevention of migraines and to treat certain irregularities in heartbeats. It can be taken orally or parentally. It reduces the heart rate and workload of cardiac muscles by blocking β1-adrenergic receptors in heart. It restricted blood flow in the brain by reducing blood vessel dilation and helpful in the treatment of migraine. It reduced the electrical activity of nervous system and made it less excitable. It also repressed the waves of electric currents that proved beneficial in the treatment of migraine aura.
Downloads
References
World Health Organization. Revision of the Monograph on Atenolol, Working Document QAS/17.700. Vol. 3. Geneva: World Health Organization; 2017.
Everything you want to know about Migraine. Available from: https:// www.healthline.com/health/migraine#takeaway [Last accessed on 2021 Jul 10].
Migraine Headaches. Available from: https://my.clevelandclinic. org/health/diseases/5005-migraine-headaches [Last accessed on 2021 Jul 05].
Types of Migraine Headaches. Available from: https://www.webmd. com/migraines-headaches/migraine-headache-types#1 [Last accessed on 2021 Jul 05].
Remington GS. The Science and practice of Pharmacy. 21st ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2005. p. 1401.
Hillery AM, Lloyd AW, Swarbrick J, editors. Drug delivery and targeting. In: For Pharmacists and Pharmaceutical Scientists. 1st ed. 2001. p. 51, 159.
Ford SM. Roach’s Introductory Clinical Pharmacology. 10th ed. Philadelphia, Pennsylvania: Lippincott Williams and Wilkins; 2013. p. 211.
Craig CR, Stitzel RE. Modern Pharmacology with Clinical Applications. 6th ed. PV publications; 2003. p. 114.
Wells BG, DiPiro JT, Schwinghammer TL, DiPiro CV. Pharmacotherapy Handbook. 7th ed. The McGraw-Hill Companies, Inc. 2009. p. 53, 121.
Dandiya PC, Kulkarni SK. Introduction to Pharmacology. 6th ed. Vallabh Prakashan, 2007. p. 139-41.
Barar FS. Essentials of Pharmacotherapeutics. 4th ed. S Chand Publishing; 2008. p. 211-5.
Mycek MJ, Harvey RA, Champe PC, Fisher BD, Cooper M. Lippincott’s Illustrated Reviews: Pharmacology. 2nd ed. Philadelphia, PA: Wolters Kluwer Health; 2000. p. 73-8.
Satoskar RS, Bhandarkar SD, Ainapure SS. Pharmacology and Pharmacotherapeutics. 18th ed. S Chand Publishers; 2003. p. 271-5.
Tripathi KD. Essentials of Medicinal Pharmacology. 6th ed. Jaypee Brothers Medical Publishers; 2008. p. 139-42.
Atenolol, Oral Tablet. Available from: https://www.healthline.com/ health/atenolol/oral-tablet [Last accessed on 2021 Apr 24].
Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardiovascular protection using beta blockers. J Am Coll Cardiol 2007;50:563-72. doi: 10.1016/j.jacc.2007.04.060, PMID 17692739.
Chrysant SG, Chrysant GS, Dimas B. Current and future study of beta blockers in treatment of hypertension. Clin Cardiol. 2008;31:249-52. doi: 10.1002/clc.20249, PMID 18543303.
Earle RR, Ayalasomayajula LU, Venkatesh P, Naidu PG, Sagar SV, Vani BS. Formulation and evaluation of atenolol orodispersable tablets by co-processed super-disintegration process. Int J Ads Pharm 2016;5:46-51.
Heel RC, Brogden RN, Speight TM, Avery GS. Atenolol: A review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension. Drugs 1979;17:425-60. doi: 10.2165/00003495- 197917060-00001, PMID 38096.
Goodman LS, Brunton LL, Blumenthal DK, Murri N, Hilal-Dandan R. Goodman and Gilman’s the Pharmacological Basis of Therapeutics. New York: McGraw-Hill Medical; 2011. p. 175-9.
Talarico G, Orecchioni S, Dallaglio K, Reggiani F, Mancuso P, Calleri A, et al. Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. Sci Rep 2016;6:18673.
Blackburn DF, Lamb DA, Eurich DT, Johnson JA, Wilson TW, Dobson RT, et al. Atenolol as initial antihypertensive therapy: An observational study comparing first-line agents. J Hypertens 2007;25:1499-505. doi: 10.1097/HJH.0b013e328136bd21, PMID 17563574.
Tabacova SA, Kimmel CA. Atenolol: Pharmacokinetic/dynamic aspects of comparative developmental toxicity. Reprod Toxicol 2002;16(1):1-7. doi: 10.1016/s0890-6238(01)00193-9, PMID 11934527.
Navare HA, Frye RF, Cooper-Dehoff RM, Shuster JJ, Hall K, Schmidt SO, et al. Atenolol exposure and risk for development of adverse metabolic effects: A pilot study. Pharmacotherapy 2010;30:872- 8. doi: 10.1592/phco.30.9.872, PMID 20795842.
McAinsh J. Clinical pharmacokinetics of atenolol. Postgrad Med J 1977;53 Suppl 3:74-8. PMID 928270.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003;289:2560-72. doi: 10.1001/jama.289.19.2560, PMID 12748199.
Wan SH, Koda RT, Maronde RF. Pharmacokinetics, pharmacology of atenolol and effect of renal disease. Br J Clin Pharmacol 1979;7:569-74. doi: 10.1111/j.1365-2125.1979.tb04644.x, PMID 465278.
Fitzgerald JD, Ruffin R, Smedstad KG, Roberts R, McAinsh J. Studies on the pharmacokinetics and pharmacodynamics of atenolol in man. Eur J Clin Pharmacol 1978;13(2):81-9. doi: 10.1007/BF00609750, PMID 658112.
Zacharias FJ, Hayes PJ, Cruickshank JM. Atenolol in hypertension: A double-blind comparison of the response to three different doses. Postgrad Med J. 1977;53(3);Suppl 3:114-5. PMID 337265.
Dollery CT. Dose-response in hypertension. Proc R Soc Med 1977;70 Suppl 5:9-10. doi: 10.1177/00359157770700S504, PMID 20919356.
Melander A, Niklasson B, Ingemarsson I, Liedholm H, Scherstén B, Sjöberg NO. Transplacental passage of atenolol in man. Eur J Clin Pharmacol 1978;14:93-4. doi: 10.1007/BF00607437, PMID 720380.
Davis E, Loiacono R, Summers RJ. The rush to adrenaline: Drugs in sport acting on the β-adrenergic system. Br J Pharmacol 2008;154:584-97. doi: 10.1038/bjp.2008.164, PMID 18500380.
Bird SR, Goebel C, Burke LM, Greaves RF. Doping in sport and exercise: Anabolic, ergogenic, health and clinical issues. Ann Clin Biochem 2016;53:196-221. doi: 10.1177/0004563215609952, PMID 26384361.
Shamliyan TA, Choi JY, Ramakrishnan R, Miller JB, Wang SY, Taylor FR, et al. Preventive pharmacologic treatments for episodic migraine in adults. J Gen Intern Med 2013;28:1225-37. doi: 10.1007/ s11606-013-2433-1, PMID 23592242.
Jackson JL, Kuriyama A, Kuwatsuka Y, Nickoloff S, Storch D, Jackson W, et al. Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis. PLoS One. 2019;14(3):e0212785. doi: 10.1371/journal.pone.0212785, PMID 30893319.
Panda S, Kar A, Banerjee T, Sharma N. Combined effects of quercetin and atenolol in reducing isoproterenol-induced cardiotoxicity in rats: Possible mediation through scavenging free radicals. Cardiovasc Toxicol 2012;12:235-42. doi: 10.1007/s12012-012-9161-3, PMID 22391854.
Moltedo JM, Kim JJ, Friedman RA, Kertesz NJ, Cannon BC. Use of a cardioselective beta-blocker for pediatric patients with prolonged QT syndrome. Pediatr Cardiol 2011;32:63-6. doi: 10.1007/s00246-010- 9819-1, PMID 20960185.
Rausova Z, Chrenova J, Mojto V, Dedik L. Quantifying pharmacodynamic interaction between atenolol and valsartan. Cent Eur J Med 2014;9:1-9. doi: 10.2478/s11536-013-0252-8.
DeMaagd G. The pharmacological management of migraine, Part 2: Preventative therapy. J Clin Pharm Ther 2008;33:480-7. PMID 19750179.
Edvardsson B. Atenolol in the prophylaxis of chronic migraine: A 3-month open-label study. Springerplus 2013;2:479. doi: 10.1186/2193-1801-2- 479, PMID 24083117.
Shirsand SB, Suresh S, Keshavshetti GG, Swamy PV, Reddy PV. Formulation and optimization of mucoadhesive bilayer buccal tablets of atenolol using simplex design method. Int J Pharm Investig 2012;2:34-41. doi: 10.4103/2230-973X.96924, PMID 23071958.
Anepu S, Duppala L, Nikhil J, Devi SJ. Formulation and evaluation of gastro retentive matrix tablets of atenolol using melt granulation technique. Int J Pharm Sci Res 2016;7:1000-12.
El-Zahry MR. A localized surface plasmon resonance sensing method for simultaneous determination of atenolol and amiloride in pharmaceutical dosage forms and urine samples. J Anal Methods Chem 2018;2018:9065249. doi: 10.1155/2018/9065249.
Satyanarayana L, Sandeepthi N. Formulation and evaluation of atenolol floating microspheres. Indo Am J Pharm Sci 2018;5:135-40.
Adhikari SNR, Panda S. Buccal patches of atenolol formulated using fenugreek (Trigonella foenum-graecum L.) seed mucilage. Polim Med 2017;47:5-11. doi: 10.17219/pim/70498, PMID 29160624.
Parashar T, Singh N. Formulation and in vitro evaluation of bilayer tablet of atenolol for biphasic drug release. Asian J Pharm Clin Res 2018;11:114-9. doi: 10.22159/ajpcr.2018.v11i5.22975.
Hasanah AN, Rahayu D, Pratiwi R, Rostinawati T, Megantara S, Saputri FA, et al. Extraction of atenolol from spiked blood serum using a molecularly imprinted polymer sorbent obtained by precipitation polymerization. Heliyon 2019;5:e01533. doi: 10.1016/j.heliyon.2019. e01533, PMID 31049441.
Salam B, El-Hiti GA, Bufaroosha M, Ahmed DS, Ahmed A, Alotaibi MH, et al. Tin complexes containing an atenolol moiety as photostabilizers for poly(vinyl chloride). Polymers (Basel) 2020;12:2923.
Salazar NC, Chen J, Rockman HA. Cardiac GPCRs: GPCR signaling in healthy and failing hearts. Biochim Biophys Acta 2007;1768:1006-18. doi: 10.1016/j.bbamem.2007.02.010, PMID 17376402.
Sprenger T, Viana M, Tassorelli C. Current prophylactic medications for migraine and their potential mechanisms of action. Neurotherapeutics 2018;15:313-23. doi: 10.1007/s13311-018-0621-8, PMID 29671241.
Abrahamsson T, Ek B, Nerme V. The beta 1- and beta 2-adrenoceptor affinity of atenolol and metoprolol. A receptor-binding study performed with different radioligands in tissues from the rat, the guinea pig and man. Biochem Pharmacol 1988;37:203-8. doi: 10.1016/0006- 2952(88)90718-6, PMID 2829913.
Agon P, Goethals P, Van Haver D, Kaufman JM. Permeability of the blood-brain barrier for atenolol studied by positron emission tomography. J Pharm Pharmacol 1991;43:597-600. doi: 10.1111/ j.2042-7158.1991.tb03545.x, PMID 1681079.
Brown HC, Carruthers SG, Johnston GD, Kelly JG, McAinsh J, McDevitt DG, Shanks RG. Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker. Clin Pharmacol Ther 1976;20:524-34. doi: 10.1002/cpt1976205524, PMID 10125.
Kato Y, Miyazaki T, Kano T, Sugiura T, Kubo Y, Tsuji A. Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J Pharm Sci 2009;98:2529-39. doi: 10.1002/jps.21618, PMID 19067419.
Niaei N, Hasanzadeh M, Shadjou N. Molecular interaction of some cardiovascular drugs with human serum albumin at physiological-like conditions: A new approach. J Mol Recognit 2018;31:e2715. doi: 10.1002/jmr.2715, PMID 29630759.
Reeves PR, McAinsh J, McIntosh DA, Winrow MJ. Metabolism of atenolol in man. Xenobiotica 1978;8:313-20. doi: 10.3109/00498257809060956, PMID 27019.
Day JL, Metcalfe J, Simpson CN. Adrenergic mechanisms in control of plasma lipid concentrations. Br Med J (Clin Res Ed) 1982;284:1145-8. doi: 10.1136/bmj.284.6323.1145, PMID 6122483.
Frishman WH. Beta-Adrenergic blockade in cardiovascular disease. J Cardiovasc Pharmacol Ther 2013;18:310-9. doi: 10.1177/1074248413484986, PMID 23637119.
Notghi A, Riemersma RA, Anderton JL, Oliver MF. Effect of pindolol versus atenolol on lipid profile in hypertensive patients. Atherosclerosis 1989;77:215-20. doi: 10.1016/0021-9150(89)90084-1, PMID 2751753.
Headache Classification Committee, Olesen J, Bousser MG, Diener HC, Dodick D, First M, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006;26:742-6. doi: 10.1111/j.1468-2982.2006.01172.x, PMID 16686915.
Hernández-Cañero A, González A, Cardonne A, Pérez-Medina T, Garcia-Barreto D. Effect of atenolol in angina pectoris of effort. Cor Vasa 1972;20:99-103. PMID 4499921.
Clinical Trials on Atenolol. Available from: https://pubchem.ncbi.nlm. nih.gov/compound/Atenolol#section=ClinicalTrials-gov [last accessed on 2021 Jan 10].
Verma RK, Viswanathan NB, Rampal A. Pharmaceutical Composition Containing Fixed Dose Combination of Atenolol with Isosorbide Mononitrate. French Patent WO2008001311A2 January 3; 2008.
Wuqing O, Jianghong S, Jianjun G, Shikong G. Compound Atenolol Nanoemulsion Antihypertensive Drug. Chinese Patent CN102631428A August 15; 2012.
Cui-tuo W, Jing-jing H, QIU Tong Q, Man-lin W, Ya-ping Y, Tao. Compound Double-layer Tablet Containing Atenolol and Amlodipine. Chinese patent CN102085201B May 7; 2014.
Dingqiang L, Sun XF, Qi SW, Xiuquan L. Method for Preparing (S)- Atenolol. Chinese Patent CN103739512A April 23; 2014.
Lei H, Zhiqiong W, Ningqing W, Zhuzhu L, Jingwei R. Atenolol Composition Freeze-Dried Tablet and Preparation Method Thereof. Chinese Patent CN104434771A March 25; 2015.
Ren BGF. Atenolol-containing Medicine Composition for Treating High Blood Pressure and Preparation Method Thereof. Chinese Patent CN105582327A May 18; 2016.
Zhang H, Ma Y, Zhang Y, Pan G. Molecularly Imprinted Polymer Nanoparticles Compatible with Biological Samples and Preparation Method Thereof. US Patent US10053531B2 August 21; 2018.
Wander GS, Chhabra ST, Kaur K. Atenolol drug profile. JAPI 2009;57:13-6.
Atenolol (Tenormin): Side Effects, Dosages, Treatment. Available from: https://www.rxlist.com/consumer_atenolol_tenormin/drugs-condition.htm# [Last accessed on 2020 Dec 28].
Atenolol Oral: Uses, Side Effects, Interactions, Pictures. Available from: https://www.webmd.com/drugs/2/drug-11035/atenolol-oral/ details [Last accessed on 2021 Jun 28].
Thorley KJ, McAinsh J, Cruickshank JM. Atenolol in the treatment of pregnancy-induced hypertension. Br J Clin Pharmacol 1981;12:725-30. doi: 10.1111/j.1365-2125.1981.tb01296.x, PMID 7332738.
Atenolol side Effects, Uses, Dosage, Overdose, Pregnancy. Available from: https://www.rxwiki.com/atenolol [Last accessed on 2021 Jul 01].
Palaniappan M. Atenolol and its Interactions with Food, Herbs and Alcohol. Available from: https://www.medindia.net/drugs/drug-food-interactions/atenolol.htm [Last accessed on 2021 Jun 28].
Lilja JJ, Raaska K, Neuvonen PJ. Effects of orange juice on the pharmacokinetics of atenolol. Eur J Clin Pharmacol 2005;61:337-40. doi: 10.1007/s00228-005-0930-9, PMID 15983823.
Gordon NF, Scott CB, Duncan JJ. Effects of atenolol versus enalapril on cardiovascular fitness and serum lipids in physically active hypertensive men. Am J Cardiol 1997;79:1065-9. doi: 10.1016/s0002- 9149(97)00048-9, PMID 9114765.
Atenolol (Professional Patient Advice). Available from: https://www. drugs.com/ppa/atenolol.html [Last accessed on 2021 Jun 28].
Samuel P, Chin B, Schoenfeld BH, Schaefer EJ, Gonasun LM. Comparison of the effect of pindolol versus propranolol on the lipid profile in patients treated for hypertension. Br J Clin Pharmacol 1987;24:s63-4.
Atenolol/Chlorthalidone Disease Interactions. Available from: https:// www.drugs.com/disease-interactions/atenolol-chlorthalidone.html [Last accessed on 2021 Jul 01].
Atenolol Disease Interactions. Available from: https://www.drugs.com/ disease-interactions/atenolol.html [Last accessed on 2021 Jul 01].
Boudonas GE. β-blockers in coronary artery disease management. Hippokratia 2010;14:231-5. PMID 21311628.
Kezerashvili A, Marzo K, De Leon JD. Beta blocker use after acute myocardial infarction in the patient with normal systolic function: when is it “ok” to discontinue? Curr Cardiol Rev 2012;8:77-84. doi: 10.2174/157340312801215764, PMID 22845818.
Pehrsson SK, Ringqvist I, Ekdahl S, Karlson BW, Ulvenstam G, Persson S. Monotherapy with amlodipine or atenolol versus their combination in stable angina pectoris. Clin Cardiol 2000;23:763-70. doi: 10.1002/clc.4960231014, PMID 11061055.
Dorian P, Angaran P. β-blockers and atrial fibrillation: Hypertension and other medical conditions influencing their use. Can J Cardiol 2014;30 Suppl 5:S38-41. doi: 10.1016/j.cjca.2013.09.029, PMID 24530215.
Tucker WD, Sankar P, Kariyanna TP. Selective Beta-1-blockers. Treasure Island, FL: StatPearls; 2021.
Rehman B, Sanchez DP, Shah S. Atenolol. Treasure Island, FL: StatPearls; 2020.
Ross DS. Beta Blockers in the Treatment of Hyperthyroidism. Available from: https://www.uptodate.com/contents/beta-blockers-in-the-treatment-of-hyperthyroidism#references [Last accessed on 2021 Jul 05].
Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society. Circulation 2017;138:e272-391.
Fitch K. Proscribed drugs at the olympic games: Permitted use and misuse (doping) by athletes. Clin Med (Lond) 2012;12:257-60. doi: 10.7861/clinmedicine.12-3-257, PMID 22783779.
Published
How to Cite
Issue
Section
Copyright (c) 2022 Seema Rohilla
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
